Cargando…

Bloodstream infections due to Carbapenem-Resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options

PURPOSE: Bloodstream infection (BSI) caused by Carbapenem-Resistant Enterobacteriaceae (CRE) are associated with poor outcomes in hematological patients. The aim of this study was to identify risk factors for mortality and evaluate the value of epidemiological feature of carbapenemases in guiding an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lining, Zhen, Sisi, Shen, Yuyan, Zhang, Tingting, Wang, Jieru, Li, Jia, Lin, Qingsong, Xiao, Zhijian, Zheng, Yizhou, Jiang, Erlie, Han, Mingzhe, Wang, Jianxiang, Feng, Sizhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197250/ https://www.ncbi.nlm.nih.gov/pubmed/37202758 http://dx.doi.org/10.1186/s12941-023-00586-y

Ejemplares similares

Assessment of mortality-related risk factors and effective antimicrobial regimens for treatment of bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa in patients with hematological diseases
por: Zhen, Sisi, et al.
Publicado: (2023)

Development of a Risk Prediction Model of Subsequent Bloodstream Infection After Carbapenem-Resistant Enterobacteriaceae Isolated from Perianal Swabs in Hematological Patients
por: Liu, Jia, et al.
Publicado: (2023)

Acinetobacter spp. bloodstream infection in hematological patients: a 10-year single-center study
por: Li, Jia, et al.
Publicado: (2023)

Clinical characteristics and risk factors of Aeromonas bloodstream infections in patients with hematological diseases
por: Xu, Chunhui, et al.
Publicado: (2022)

P1527: ASSESSMENT OF RISK FACTORS AND ANTIMICROBIAL THERAPY FOR CARBAPENEM-RESISTANT PSEUDOMONAS AERUGINOSA BLOODSTREAM INFECTIONS IN HEMATOLOGICAL PATIENTS
por: Chen, Zhangjie, et al.
Publicado: (2023)

P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)
por: Runzhi, MA, et al.
Publicado: (2023)

Socioeconomic Burden of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Zhu, Yunying, et al.
Publicado: (2021)

High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic children with hematological diseases
por: Liu, Li-Peng, et al.
Publicado: (2023)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
por: Morrill, Haley J., et al.
Publicado: (2015)

P1304: TREATMENT WITH COMBINATION OF RITUXIMAB AND INTRAVENOUS Γ GLOBULIN IS EFFECTIVE IN PROMOTING ENGRAFTMENT IN DONOR SPECIFIC ANTIBODY POSITIVE PATIENTS RECEIVING HAPLOIDENTICAL STEM CELL TRANSPLANT
por: Shen, Yuyan, et al.
Publicado: (2023)

Clinical Characteristics and Risk Factors for Bloodstream Infection Due to Carbapenem-Resistant Klebsiella pneumoniae in Patients with Hematologic Malignancies
por: Zhang, Piaopiao, et al.
Publicado: (2020)

Clinical and Mortality Risk Factors in Bloodstream Infections with Carbapenem-Resistant Enterobacteriaceae
por: Li, Xiaopeng, et al.
Publicado: (2017)

Infections Caused by Carbapenem-Resistant Enterobacteriaceae: An Update on Therapeutic Options
por: Sheu, Chau-Chyun, et al.
Publicado: (2019)

Bloodstream Infections in Patients with Rectal Colonization by Carbapenem-Resistant Enterobacteriaceae: A Prospective Cohort Study
por: Chu, Wenwen, et al.
Publicado: (2022)

Clinical Characteristics and Associated Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection
por: Ahn, Jin Young, et al.
Publicado: (2023)

P1511: MUCORMYCOSIS IN PATIENTS WITH HEMATOLOGIC DISEASES: HOW TO IMPROVE THE PROGNOSIS
por: Wang, Jieru, et al.
Publicado: (2023)

Construction of a Risk Prediction Model for Subsequent Bloodstream Infection in Intestinal Carriers of Carbapenem-Resistant Enterobacteriaceae: A Retrospective Study in Hematology Department and Intensive Care Unit
por: Wang, Yue, et al.
Publicado: (2021)

Clinical Features and Treatment Progress of Invasive Mucormycosis in Patients with Hematological Malignancies
por: Yang, Nuobing, et al.
Publicado: (2023)

Ruxolitinib as an Effective and Steroid-Sparing First-Line Treatment in Newly Diagnosed BOS Patients After Hematopoietic Stem Cell Transplantation
por: Zhang, Xiaoyu, et al.
Publicado: (2022)

Emergency Combination of Four Drugs for Bloodstream Infection Caused by Carbapenem-Resistant Enterobacteriaceae in Severe Agranulocytosis Patients with Hematologic Malignancies after Hematopoietic Stem Cell Transplantation
por: Li, Xiaofan, et al.
Publicado: (2020)

Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan
por: Wang, Jann-Tay, et al.
Publicado: (2015)

Carbapenem-Resistant Enterobacteriaceae—Implications for Treating Acute Leukemias, a Subgroup of Hematological Malignancies
por: Storhaug, Kristin Ølfarnes, et al.
Publicado: (2021)

Active Screening of Intestinal Colonization of Carbapenem-Resistant Enterobacteriaceae for Subsequent Bloodstream Infection in Allogeneic Hematopoietic Stem Cell Transplantation
por: Cao, Weijie, et al.
Publicado: (2022)

Carbapenem-Resistant Enterobacteriaceae Bloodstream Infection Treated Successfully With High-Dose Meropenem in a Preterm Neonate
por: Wu, Yue-E, et al.
Publicado: (2020)

Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
por: Guo, Wenjing, et al.
Publicado: (2023)

Treatment for infections with carbapenem-resistant Enterobacteriaceae: what options do we still have?
por: Yamamoto, Michele, et al.
Publicado: (2014)

Therapeutic Options for the Treatment of Carbapenem-resistant Enterobacteriaceae Infections: Hope in the Times of Hype and Despair
por: Ansari, Abdul S
Publicado: (2021)

Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematologic Malignancies
por: Yuan, Fangfang, et al.
Publicado: (2023)

Comparison of hematopoietic stem cell transplantation and immunosuppressive therapy as the first-line treatment option for patients with severe hepatitis−associated aplastic anemia
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

Resistance Pattern of Carbapenem on Enterobacteriaceae
por: Pokharel, Khilasa, et al.
Publicado: (2018)

Clinical and Microbiological Characteristics of Community-Onset Carbapenem-Resistant Enterobacteriaceae Isolates
por: Hu, Hangbin, et al.
Publicado: (2020)

2410. Clinical Outcomes Associated With Various Treatment Options for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
por: Bandali, Aiman, et al.
Publicado: (2018)

Emerging Carbapenem-Resistant Enterobacteriaceae Infection, Its Epidemiology and Novel Treatment Options: A Review
por: Tilahun, Mihret, et al.
Publicado: (2021)

2416. Risk Factors and Outcomes of Bacteremia Caused by Carbapenem-Resistant Enterobacteriaceae Compared With Carbapenem Susceptible Enterobacteriaceae
por: Mahmood, Syed Faisal
Publicado: (2018)

Mortality Impact of CLSI Carbapenem Breakpoint Changes in Enterobacteriaceae Bloodstream Infections: a Patient-level Analysis of Published Data
por: O’Donnell, J Nicholas, et al.
Publicado: (2017)

Carbapenem-resistant Enterobacteriaceae bloodstream infections: A case-control study from a pediatric referral hospital in Argentina
por: Ruvinsky, Silvina, et al.
Publicado: (2022)

Vital Signs: Carbapenem-Resistant Enterobacteriaceae
por: Jacob, Jesse T., et al.
Publicado: (2013)

P1308: RUXOLITINIB AS GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN APLASTIC ANEMIA PATIENTS
por: Zhang, Xiaoyu, et al.
Publicado: (2023)

479 Clinical outcomes in patients with extended-spectrum-beta-lactamase-producing (ESBL) Enterobacteriaceae bloodstream infections (ESB) treated with carbapenems (CP) and non-carbapenems (NC)
por: Chin, Judy, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n59g1pdl25v2qcdk8dr47ppc36